Page last updated: 2024-08-21

fluorobenzenes and Parkinson Disease

fluorobenzenes has been researched along with Parkinson Disease in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boger, HA; Corum, D; Lynn, MK; Schnellmann, RG; Scholpa, NE	1
Bonhaus, DW; McFarland, K; Price, DL	1
Orr, JD	1

Reviews

1 review(s) available for fluorobenzenes and Parkinson Disease

Article	Year
Statins in the spectrum of neurologic disease. Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides	2008

Article

Year

Statins in the spectrum of neurologic disease.

Current atherosclerosis reports, 2008, Volume: 10, Issue:1

Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides

2008

Other Studies

2 other study(ies) available for fluorobenzenes and Parkinson Disease

Article	Year
5-HT British journal of pharmacology, 2018, Volume: 175, Issue:2 Topics: Animals; Carbazoles; Corpus Striatum; Fluorobenzenes; Locomotion; Male; Mice; Mitochondria; Organelle Biogenesis; Oxidopamine; Parkinson Disease; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase	2018
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behavioural pharmacology, 2011, Volume: 22, Issue:7 Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea	2011

Article

Year

5-HT

British journal of pharmacology, 2018, Volume: 175, Issue:2

Topics: Animals; Carbazoles; Corpus Striatum; Fluorobenzenes; Locomotion; Male; Mice; Mitochondria; Organelle Biogenesis; Oxidopamine; Parkinson Disease; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase

2018

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.

Behavioural pharmacology, 2011, Volume: 22, Issue:7

Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea

2011